Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells 12,314 Shares of Stock

Key Points

• Kura Oncology insider Mollie Leoni sold 12,314 shares of stock at an average price of $8.94, totaling approximately $110,087, which represents a 7.21% decrease in their ownership.
• The company's shares traded down to $8.97 with a market cap of $778.60 million, and it reported a loss of $0.75 earnings per share, missing estimates significantly.
• Recent analyst ratings for Kura Oncology include a mix of "hold," "buy," and "outperform" recommendations, with an average price target of $24.10.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Mollie Leoni sold 12,314 shares of the business's stock in a transaction on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $110,087.16. Following the transaction, the insider directly owned 158,439 shares of the company's stock, valued at $1,416,444.66. This trade represents a 7.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kura Oncology Price Performance

Shares of Kura Oncology stock traded down $0.08 during trading on Monday, reaching $8.97. 2,168,205 shares of the company's stock were exchanged, compared to its average volume of 1,613,537. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $19.93. The company has a market cap of $778.60 million, a P/E ratio of -3.97 and a beta of 0.19. The firm's 50-day moving average price is $7.39 and its 200 day moving average price is $6.65.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to the consensus estimate of $64.95 million. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

KURA has been the subject of several recent research reports. Guggenheim initiated coverage on Kura Oncology in a research note on Thursday, September 4th. They issued a "neutral" rating for the company. Wall Street Zen upgraded Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research report on Friday, June 20th. JMP Securities cut their target price on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research report on Monday, August 11th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and a consensus price target of $24.10.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently made changes to their positions in KURA. Tower Research Capital LLC TRC boosted its stake in Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company's stock valued at $70,000 after buying an additional 9,958 shares during the period. Rangeley Capital LLC bought a new stake in Kura Oncology during the second quarter valued at $669,000. Man Group plc boosted its stake in Kura Oncology by 234.7% during the second quarter. Man Group plc now owns 522,388 shares of the company's stock valued at $3,014,000 after buying an additional 366,324 shares during the period. EcoR1 Capital LLC boosted its stake in Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company's stock valued at $24,234,000 after buying an additional 1,559,702 shares during the period. Finally, Engineers Gate Manager LP boosted its stake in Kura Oncology by 8.7% during the second quarter. Engineers Gate Manager LP now owns 62,564 shares of the company's stock valued at $361,000 after buying an additional 5,028 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.